Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. more
Time Frame | CYTK | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.56% | -2.06% | -0.55% |
1-Month Return | -10.74% | -1.92% | 2.72% |
3-Month Return | -17.13% | -10.4% | 7.66% |
6-Month Return | -10.74% | -4.6% | 10.15% |
1-Year Return | 28.46% | 4.06% | 27.53% |
3-Year Return | 17.37% | 1.94% | 32.31% |
5-Year Return | 352.29% | 36.48% | 89.2% |
10-Year Return | 848.06% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 26.87M | 55.83M | 70.43M | 94.59M | 7.53M | [{"date":"2019-12-31","value":28.41,"profit":true},{"date":"2020-12-31","value":59.02,"profit":true},{"date":"2021-12-31","value":74.46,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.96,"profit":true}] |
Cost of Revenue | 86.13M | 96.95M | 159.94M | 240.81M | 330.12M | [{"date":"2019-12-31","value":26.09,"profit":true},{"date":"2020-12-31","value":29.37,"profit":true},{"date":"2021-12-31","value":48.45,"profit":true},{"date":"2022-12-31","value":72.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (59.26M) | (41.12M) | (89.51M) | (146.22M) | (322.59M) | [{"date":"2019-12-31","value":-5925700000,"profit":false},{"date":"2020-12-31","value":-4112300000,"profit":false},{"date":"2021-12-31","value":-8951000000,"profit":false},{"date":"2022-12-31","value":-14622500000,"profit":false},{"date":"2023-12-31","value":-32259300000,"profit":false}] |
Gross Margin | (220.55%) | (73.66%) | (127.09%) | (154.59%) | (4284.10%) | [{"date":"2019-12-31","value":-220.55,"profit":false},{"date":"2020-12-31","value":-73.66,"profit":false},{"date":"2021-12-31","value":-127.09,"profit":false},{"date":"2022-12-31","value":-154.59,"profit":false},{"date":"2023-12-31","value":-4284.1,"profit":false}] |
Operating Expenses | 39.61M | 52.82M | 96.80M | 177.98M | 173.61M | [{"date":"2019-12-31","value":22.26,"profit":true},{"date":"2020-12-31","value":29.68,"profit":true},{"date":"2021-12-31","value":54.39,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true}] |
Operating Income | (98.87M) | (93.94M) | (186.31M) | (324.20M) | (496.20M) | [{"date":"2019-12-31","value":-9886700000,"profit":false},{"date":"2020-12-31","value":-9394300000,"profit":false},{"date":"2021-12-31","value":-18631300000,"profit":false},{"date":"2022-12-31","value":-32420200000,"profit":false},{"date":"2023-12-31","value":-49620500000,"profit":false}] |
Total Non-Operating Income/Expense | (45.65M) | (66.69M) | (58.00M) | (104.57M) | (60.95M) | [{"date":"2019-12-31","value":-4565000000,"profit":false},{"date":"2020-12-31","value":-6669400000,"profit":false},{"date":"2021-12-31","value":-5800200000,"profit":false},{"date":"2022-12-31","value":-10456700000,"profit":false},{"date":"2023-12-31","value":-6095000000,"profit":false}] |
Pre-Tax Income | (121.69M) | (127.29M) | (215.31M) | (388.95M) | (526.24M) | [{"date":"2019-12-31","value":-12169200000,"profit":false},{"date":"2020-12-31","value":-12729000000,"profit":false},{"date":"2021-12-31","value":-21531400000,"profit":false},{"date":"2022-12-31","value":-38895500000,"profit":false},{"date":"2023-12-31","value":-52624400000,"profit":false}] |
Income Taxes | 27.36M | 36.84M | 27.06M | 13.60M | 11.72M | [{"date":"2019-12-31","value":74.26,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":73.43,"profit":true},{"date":"2022-12-31","value":36.9,"profit":true},{"date":"2023-12-31","value":31.82,"profit":true}] |
Income After Taxes | (149.05M) | (164.13M) | (242.37M) | (402.55M) | (537.97M) | [{"date":"2019-12-31","value":-14905200000,"profit":false},{"date":"2020-12-31","value":-16413500000,"profit":false},{"date":"2021-12-31","value":-24237000000,"profit":false},{"date":"2022-12-31","value":-40255200000,"profit":false},{"date":"2023-12-31","value":-53796810500,"profit":false}] |
Income From Continuous Operations | (100.95M) | (104.58M) | (202.42M) | (332.27M) | (526.73M) | [{"date":"2019-12-31","value":-10095500000,"profit":false},{"date":"2020-12-31","value":-10457700000,"profit":false},{"date":"2021-12-31","value":-20242200000,"profit":false},{"date":"2022-12-31","value":-33227400000,"profit":false},{"date":"2023-12-31","value":-52672800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (149.05M) | (164.13M) | (242.37M) | (402.55M) | (526.24M) | [{"date":"2019-12-31","value":-14905200000,"profit":false},{"date":"2020-12-31","value":-16413500000,"profit":false},{"date":"2021-12-31","value":-24237000000,"profit":false},{"date":"2022-12-31","value":-40255200000,"profit":false},{"date":"2023-12-31","value":-52624400000,"profit":false}] |
EPS (Diluted) | (2.12) | (2.01) | (2.83) | (4.22) | (5.45) | [{"date":"2019-12-31","value":-212,"profit":false},{"date":"2020-12-31","value":-201,"profit":false},{"date":"2021-12-31","value":-283,"profit":false},{"date":"2022-12-31","value":-422,"profit":false},{"date":"2023-12-31","value":-545,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CYTK | |
---|---|
Cash Ratio | 9.21 |
Current Ratio | 9.28 |
Quick Ratio | 9.28 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CYTK | |
---|---|
ROA (LTM) | -30.13% |
ROE (LTM) | -572.15% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CYTK | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.01 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.01 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CYTK | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1699.64 |
P/B | 60.31 |
Price/FCF | NM |
EV/R | 1682.71 |
EV/Ebitda | NM |
PEG | NM |
Cytokinetics Inc (CYTK) share price today is $46.36
Yes, Indians can buy shares of Cytokinetics Inc (CYTK) on Vested. To buy Cytokinetics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CYTK stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cytokinetics Inc (CYTK) via the Vested app. You can start investing in Cytokinetics Inc (CYTK) with a minimum investment of $1.
You can invest in shares of Cytokinetics Inc (CYTK) via Vested in three simple steps:
The 52-week high price of Cytokinetics Inc (CYTK) is $110.25. The 52-week low price of Cytokinetics Inc (CYTK) is $36.24.
The price-to-earnings (P/E) ratio of Cytokinetics Inc (CYTK) is
The price-to-book (P/B) ratio of Cytokinetics Inc (CYTK) is 60.31
The dividend yield of Cytokinetics Inc (CYTK) is 0.00%
The market capitalization of Cytokinetics Inc (CYTK) is $5.64B
The stock symbol (or ticker) of Cytokinetics Inc is CYTK